Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9249685 | 0.88 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL12733023 | 0.80 | CYP1A2 (0.47) | CYP1A2KDM4E | |
| SCHEMBL12733025 | 0.80 | CYP1A2 (0.47) | CYP1A2KDM4E | |
| SCHEMBL1045193 | 0.80 | CYP1A2 (0.47) | CYP1A2KDM4E | |
| SCHEMBL12733024 | 0.80 | CYP1A2 (0.47) | CYP1A2KDM4E | |
| SCHEMBL12733021 | 0.80 | CYP1A2 (0.47) | CYP1A2KDM4E | |
| SCHEMBL28143301 | 0.80 | CYP1A2 (0.52) | CYP1A2 | |
| SCHEMBL19558491 | 0.80 | CYP1A2 (0.52) | CYP1A2 | |
| SCHEMBL6913788 | 0.79 | MMP1 (0.31) | — | |
| SCHEMBL10125737 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-8822424-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8658606-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8653042-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524689-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283208-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120214760-A1 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885KDM4E 2729/4885GAA 253/4885 |
| US-20120135948-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1336/4885KDM4E 3622/4885GAA 200/4885 |
| US-20120283208-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QTRT1 | CYP1A2 1081/4885KDM4E 3771/4885GAA 160/4885 |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1551/4885KDM4E 3617/4885GAA 148/4885 |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885KDM4E 2729/4885GAA 253/4885 |
| US-20120214760-A1 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | NPEPPS, PIGS, ATP6V1B1 | CYP1A2 3326/4885KDM4E 4510/4885GAA 36/4885 |
| US-20110275586-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, MRPS23 | CYP1A2 1195/4885KDM4E 3232/4885GAA 234/4885 |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | CYP1A2 2298/4885KDM4E 2729/4885GAA 253/4885 |
| US-20120172332-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1267/4885KDM4E 3626/4885GAA 168/4885 |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | CYP1A2 1496/4885KDM4E 3577/4885GAA 140/4885 |
| US-20120283207-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QTRT1 | CYP1A2 1081/4885KDM4E 3771/4885GAA 160/4885 |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, QARS1, NQO2 | CYP1A2 1530/4885KDM4E 4047/4885GAA 250/4885 |
| US-20120208781-A1 | AMINOGLYCOSIDE DOSING REGIMENS | ATP6V1B1, GLS, NRDC | CYP1A2 2047/4885KDM4E 4645/4885GAA 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.